TX-DENTALMONITORING
The company that pioneered the field of virtual orthodontics and has been the market leader since 2014 is revolutionizing the industry once again with the only available AI-based virtual monitoring solution applicable to both aligner and braces treatments of all types and brands.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210601005494/en/
In an industry where a vast majority of practices are mixed users, the DentalMonitoring’s solution now allows dental professionals — whether in private practices or DSOs — to take full control of not only their aligner and but also all their braces cases. As a result DentalMonitoring expands its addressable market by close to 75%, helping more practices scale up their business, become more efficient and deliver an outstanding patient experience.
“Our solution has made yet another major breakthrough, and we are proud to unveil a new suite of functionalities of our platform,” says Philippe Salah, CEO of DentalMonitoring. “Dental professionals can now monitor all their aligner and braces cases independent of brand with the same, highly scalable AI-driven workflow. In addition to monitoring treatment progress, they can now actively define and monitor clinical goals for each patient. This results in more active control, productivity and a new level of safety and confidence for their practice: a real mindset shift for our industry.”
Salah continues: “Doctors now have complete control over all orthodontic treatment and can automatically track inter arch parameters such as the overbite, the overjet, the transverse or class correction of patients or detect the archwire and auxiliaries passivity in addition to the intra arch parameters they were already able to track with our solution. Dental professionals can virtualize and automate all non-clinical procedures and schedule appointments only when needed. At the same time, the patients’ compliance and engagement are improved, thanks to the complete revamping of our highly rated patient app.”
As the demand for remote care technology increases within the dental industry, DentalMonitoring continues to lead the way with its virtual practice solutions designed to engage, convert and monitor patients. Powered by AI and a database of over half a billion patient photographs, the virtual practice solutions are designed to give dental professionals the flexibility and convenience they need to safely address all sorts of orthodontic patient cases and optimize chair time.
About DentalMonitoring:
DentalMonitoring’s promise is to help all dental professionals improve their practice efficiency, optimize orthodontic treatment plans and enhance the patient experience thanks to its virtual practice solutions:
- SmileMate , maximizes lead engagement and patient conversion, with the ability for dental professionals to triage and qualify patients even before they step into the practice.
- DentalMonitoring , its flagship solution, monitors all treatments remotely, from aligners and braces of all brands to retention and hygiene.
DentalMonitoring operates across the United States, Europe and Asia with five offices: in Austin, TX, London, Paris, Hong Kong and Sydney.
To learn more about DentalMonitoring, visit www.dental-monitoring.com
DentalMonitoring, Smilemate and Vision are products designed and manufactured by Dental Monitoring SAS, under the DentalMind® branding for Health Care Professional.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210601005494/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom